Olink®Part of Thermo Fisher Scientific
Powerful, NGS-based proteomics - effortlessly uncover meaningful insights
A unique combination of specificity and scalability enables high-throughput, multiplex protein biomarker analysis.
Next-generation high-throughput proteomics empowers genetically-informed assessment of protein causality and the confident identification of novel drug targets.
Join Olink users, consortia, events and webinars to share insights and accelerate biomarker discovery.
Comprehensive statistical analysis & data visualization tools
Over 4,000 and growing rapidly – covering all major disease areas
Your source for Olink’s terms, privacy policies, and compliance details
Filters
Brain, Behavior, and Immunity, 2014Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment
Isgren A., Jakobsson J., Pålsson E. et al.
Olink Target 96
International Orthopaedics, 2014Exogenous BMP7 corrects plasma iron overload and bone loss in Bmp6-/- mice
Pauk M., Grgurevic L., Brkljacic J. et al.
Nature Communications, 2014Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs
Enroth S., Johansson ?., Enroth S. et al.
PLoS ONE, 2014Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability
Assarsson E., Lundberg M., Holmquist G. et al.
PROTEOMICS, 2014Antibody‐based proteomics and biomarker research—Current status and limitations
Solier C., Langen H.
4265 publications
Items per page
4261-4265 of 4265 publications